In the present study, c-kit mutations were identified in six of the 12 AML-ETO-positive samples, yielding a positivity rate (50%) comparable with those previously reported; 12.8–46.8% (19–21). This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.